We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Clinical study of camrelizumab combined with docetaxel and carboplatin as a neoadjuvant treatment for locally advanced oesophageal squamous cell carcinoma.
- Authors
Zhang, Guo-Liang; Zhu, Qi-Kun; Ma, Tian-You; Weng, Chen-Gang; Zhang, Dan-Dan; Zeng, Hui; Wang, Tao; Gao, Feng; Mi, Li-Li; Wang, Rui
- Abstract
Herein, we aimed to evaluate the efficacy and safety of camrelizumab combined with docetaxel and carboplatin as a neoadjuvant treatment for locally advanced oesophageal squamous cell carcinoma (OSCC). Fifty-one patients with OSCC, treated from July 2020 to October 2022, were analyzed. Of them, 41 patients underwent surgery 4–8 weeks after undergoing two cycles of camrelizumab (200 mg IV Q3W) combined with docetaxel (75 mg/m2 IV Q3W) and carboplatin (area under the curve = 5–6 IV Q3W). The primary endpoint was the pathological complete response rate. All 51 patients (100%) experienced treatment-related grades 1–2 adverse events, and 2 patients (3.9%) experienced grade 4 events (including elevated alanine transaminase/aspartate transferase levels and Guillain–Barre syndrome). Fifty patients were evaluated for the treatment efficacy. Of them, 13 achieved complete response, and the objective response rate was 74%. Only 41 patients underwent surgical treatment. The pathological complete response rate was 17.1%, the major pathological response rate was 63.4%, and the R0 resection rate was 100%. Approximately 22% of the patients had tumor regression grades 0. Eight patients (19.5%) developed surgery-related complications. The median follow-up time was 18 months (range: 3–29 months). Four patients experienced disease progression, while four died. The median disease-free survival and overall survival were not reached. Camrelizumab combined with docetaxel and carboplatin is an effective and safe neoadjuvant treatment for locally advanced OSCC. This regimen may afford a potential strategy to treat patients with locally advanced OSCC.
- Subjects
NEOADJUVANT chemotherapy; SQUAMOUS cell carcinoma; DOCETAXEL; CARBOPLATIN; ALANINE aminotransferase
- Publication
Diseases of the Esophagus, 2024, Vol 37, Issue 4, p1
- ISSN
1120-8694
- Publication type
Article
- DOI
10.1093/dote/doad073